Skip to main content

Table 1 Characteristics of patients in burst suppression and non-burst suppression groups

From: Does burst-suppression achieve seizure control in refractory status epilepticus?

Variable Burst suppression group Non-burst suppression group P-valueb
n (%) n (%)
Age (years)    0.136
 < 30 5 (19.2) 8 (32.0)  
 30–60 9 (34.6) 12 (48.0)  
 > 60 12 (46.2) 5 (20.0)  
Sex    0.068
 male 16 (61.5) 9 (36.0)  
 female 10 (38.5) 16 (64.0)  
Etiology    0.353
 encephalitis 13 (50) 10 (40.0)  
 metabolic 10 (38.5) 8 (32.0)  
 static lesion 1 (3.8) 5 (20.0)  
 drug withdrawal 2 (7.7) 2 (8.0)  
History of epilepsy    0.067
 yes 7 (26.9) 13 (52.0)  
 no 19 (73.1) 12 (48.0)  
Number of antiepileptic drugs (before midazolam therapy)    0.35
 2 10 (38.5) 5 (20.0)  
 3 11 (42.3) 14 (56.0)  
 4 5 (19.2) 6 (24.0)  
Status epilepticus severity score    0.27
 3 7 (29.9) 12 (48.0)  
 4 15 (57.7) 11 (44.0)  
  > 4 4 (15.4) 2 (8.0)  
Dose of midazolam (mg/kg/day)    0.350
  < 0.6 10 (38.5) 5 (20.0)  
 0.6–1.2 11 (42.3) 14 (56.0)  
  > 1.2 5 (19.2) 6 (24.0)  
Time to midazolam therapy (hours)    0.676
  ≤ 24 14 (53.8) 12 (48.0)  
  > 24 12 (46.2) 13 (52.0)  
Length of hospital stay (days)    0.747
  < 14 11 (42.3) 8 (32.0)  
 14–21 9 (34.6) 10 (40.0)  
  > 21 6 (23.1) 7 (28.0)  
Breakthrough seizure    < 0.001
 no 19 (73.1) 1 (4.0)  
 yes 7 (26.9) 24 (96.0)  
Withdrawal seizure    0.061
 no 12 (46.2) 18 (72.0)  
 yes 14 (53.8) 7 (28.0)  
Pulmonary complication    0.657
 no 14 (53.8) 15 (60.0)  
 yes 12 (46.2) 10 (40.0)  
Cardiac complication    0.789
 no 20 (76.9) 20 (80.0)  
 yes 6 (23.1) 5 (20.0)  
Fever/infection    0.301
 no 14 (53.8%) 17 (68%)  
 yes 12 (46.2%) 8 (32%)  
In-hospital mortality    0.029
 alive 12 (46.2) 19 (76.0)  
 dead 14 (53.8) 6 (24.0)  
Functional outcome at 3 monthsa    0.379
 good 7 (58.3) 8 (42.1)  
 poor 5 (41.7) 11 (57.9)  
  1. aexcluding dead patients
  2. bChi-square test